CCIA
OLMA icon

Campbell & Co Investment Adviser’s Olema Pharmaceuticals OLMA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,556
Closed -$889K – 1322
2025
Q4 		$889K Buy
35,556
+6,508
+22% +$116K 0.04% 611
2025
Q3 		$284K Buy
+29,048
New +$174K 0.02% 922

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Campbell & Co Investment Adviser's OLMA Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Olema Pharmaceuticals (OLMA) in Q1 2026, closing a stake of 35,556 shares — an estimated $889K sold.

Campbell & Co Investment Adviser first reported a position in OLMA in Q3 2025 and held it in 2 quarters. The position peaked at $889K in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Olema Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 35,556 Olema Pharmaceuticals shares in Q1 2026, an estimated $889K.
  • Campbell & Co Investment Adviser first reported a position in Olema Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Olema Pharmaceuticals position peaked at $889K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.